Response by Kario et al to Letter Regarding Article, "Nighttime Blood Pressure Phenotype and Cardiovascular Prognosis: Practitioner-Based Nationwide JAMP Study"

Kazuomi Kario; Hiroshi Kanegae; Satoshi Hoshide

doi:10.1161/CIRCULATIONAHA.121.053993

Response by Kario et al to Letter Regarding Article, "Nighttime Blood Pressure Phenotype and Cardiovascular Prognosis: Practitioner-Based Nationwide JAMP Study"

Kazuomi Kario, Hiroshi Kanegae, Satoshi Hoshide

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	E982-E983
Journal	Circulation
Volume	143
Issue number	21
DOIs	https://doi.org/10.1161/CIRCULATIONAHA.121.053993
State	Published - 25 May 2021
Externally published	Yes

Access to Document

10.1161/CIRCULATIONAHA.121.053993

Cite this

@article{e1c466f1beb84c58ac355a7291c36222,

title = "Response by Kario et al to Letter Regarding Article, {"}Nighttime Blood Pressure Phenotype and Cardiovascular Prognosis: Practitioner-Based Nationwide JAMP Study{"}",

author = "Kazuomi Kario and Hiroshi Kanegae and Satoshi Hoshide",

note = "Funding Information: K.K. has received research grants from A\&D, Asteras Pharma, Taisho Pharmaceutical, and Boehringer Ingelheim Japan, and honoraria from A\&D, AstraZeneca, Kowa, Sanofi, Mitsubishi Tanabe Pharma, and Boehringer Ingelheim Japan, outside the submitted work. The other authors report no conflicts.",

year = "2021",

month = may,

day = "25",

doi = "10.1161/CIRCULATIONAHA.121.053993",

language = "English",

volume = "143",

pages = "E982--E983",

journal = "Circulation",

issn = "0009-7322",

publisher = "Lippincott Williams and Wilkins",

number = "21",

}

TY - JOUR

T1 - Response by Kario et al to Letter Regarding Article, "Nighttime Blood Pressure Phenotype and Cardiovascular Prognosis

T2 - Practitioner-Based Nationwide JAMP Study"

AU - Kario, Kazuomi

AU - Kanegae, Hiroshi

AU - Hoshide, Satoshi

N1 - Funding Information: K.K. has received research grants from A&D, Asteras Pharma, Taisho Pharmaceutical, and Boehringer Ingelheim Japan, and honoraria from A&D, AstraZeneca, Kowa, Sanofi, Mitsubishi Tanabe Pharma, and Boehringer Ingelheim Japan, outside the submitted work. The other authors report no conflicts.

PY - 2021/5/25

Y1 - 2021/5/25

UR - https://www.scopus.com/pages/publications/85106910822

U2 - 10.1161/CIRCULATIONAHA.121.053993

DO - 10.1161/CIRCULATIONAHA.121.053993

M3 - Letter

C2 - 34029139

AN - SCOPUS:85106910822

SN - 0009-7322

VL - 143

SP - E982-E983

JO - Circulation

JF - Circulation

IS - 21

ER -